First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer - Timothy A. Yap; Jonathan W. Goldman; Shaveta Vinayak; Antoaneta Tomova; Erika Hamilton; Yoichi Naito; Antonio Giordano; Igor Bondarenko; Toshinari Yamashita; Li Zhou; Allison Moreau; Heather Neumann; et al. (Clinical Cancer Research, 2025)